GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced that it signed a Memorandum of Understanding (MOU) with LabConnect to expand global clinical trial collaboration. LabConnect is a global central laboratory and clinical trial samples solutions partner.

Built on a collaborative relationship spanning more than 20 years, this agreement aims to improve the operational efficiency of global clinical trial projects by linking the regional capabilities and expertise of both companies across North America and the Asia-Pacific (APAC) region.

The signing ceremony, held at GCCL's headquarters, was attended by key executives from both organizations, including GCCL CEO Kwan-goo Cho and from LabConnect, Jeff Mayhew, Founder and Strategic Commercial Advisor, and Joshua Gentile, Senior Vice President, Head of Commercial Sales and Marketing. During the event, the two companies shared their core services and future visions, discussing key collaborative initiatives, including:

• Identifying potential clients and supporting sales within each region
• Integrating global clinical trials and central laboratory services
• Cooperating on project management and client communications
• Formulating joint marketing strategies and identifying new business opportunities

Under this agreement, GCCL and LabConnect plan to establish a mutual collaboration framework leveraging their respective regional strengths and partner relationships. Furthermore, the companies intend to drive joint sales and marketing initiatives while setting up shared systems and processes for client responses and project management.

"Through this collaboration with GCCL, we expect to simplify and orchestrate complex studies conducted in South Korea and the Asia-Pacific region," said Jeff Mayhew, Founder and Strategic Commercial Advisor of LabConnect. "Pairing GCCL's laboratory and logistics strength with our global alliance of clinical and specialty laboratories, along with proactive sample logistics oversight and intervention, provides sponsors a more coordinated path for multi-regional studies."

Kwan-goo Cho, CEO of GCCL, stated, "This MOU marks the starting point of connecting GCCL's execution capabilities in the APAC region with LabConnect's comprehensive global alliance of clinical and specialty laboratories. We are committed to building a practical collaborative framework spanning joint sales, project execution, and client management to accelerate our global clinical trial business."